Sauvie Inc.

Biotechnology Research

Short Hills, NJ 572 followers

Developing transformational therapies with next generation antibodies.

View all 6 employees

About us

Sauvie Inc. is a mission-driven biotechnology company with a focus to discover, develop and deliver transformational therapies harnessing next generation antibodies. We're a team of passionate individuals committed to developing transformational therapies to save lives. Our core values drive decisions we make and following the science, having intellectual curiosity and integrity are at the heart of our approach. We believe this ensures that we prioritize what truly matters - creating value for patients, healthcare professionals, employees, investors and the wider community. Sauvie's values are: 1) Follow the science 2) Intellectual curiosity 3) Integrity

Website: www.sauvieinc.com
External link for Sauvie Inc.
Industry: Biotechnology Research
Company size: 2-10 employees
Headquarters: Short Hills, NJ
Type: Privately Held
Founded: 2022
Specialties: Research, Biotechnology, Sustainable Growth, Cancer Therapy, Development, Commercialization, Partnering, Business Development, Stomach Cancer, Endometrial Cancer, Hematology, R&D, Innate Immunity, Immunotherapy, and NextGenAntibodies

Products

Single-domain antibody (sdAb)

Single-domain antibodies (sdAbs) have unique properties like the finger-like region that can access cryptic epitopes. Sauvie is focused on harnessing the advantageous properties of sdAbs to develop next generation cancer therapies.

Locations

Primary

51 JFK Parkway

First Floor West

Short Hills, NJ 07078, US

Get directions

Employees at Sauvie Inc.

See all employees

Updates

Sauvie Inc. reposted this

Rutgers Research

6,560 followers
1mo
Report this post
𝗥𝗨𝗧𝗚𝗘𝗥𝗦 𝗥𝗘𝗦𝗘𝗔𝗥𝗖𝗛𝗘𝗥𝗦: Are you thinking about launching a start-up🚀? Would you like to learn more about the process of launching a start-up🚀? If so, the next Rutgers Innovation Road to Commercialization free webinar is for you! 𝐿𝑎𝑢𝑛𝑐ℎ𝑖𝑛𝑔 𝑎 𝑆𝑡𝑎𝑟𝑡-𝑢𝑝 will take place on Tuesday, Nov. 19, from 10-11:30 a.m. The webinar will feature a panel of experts, including startup founders and legal counsel, who will discuss the steps you should take when creating your own company, and answer any questions you may have. Click here to register: https://lnkd.in/d_rw4s24 #RutgersResearch #RutgersInnovation
Like Comment Share
Sauvie Inc.

572 followers
1mo
Report this post
Interesting research from Uppsala University and Key2Brain AB about single-domain antibody (VHH)-scFv fusions penetrating the blood-brain-barrier. We're cheering on to bring hope for patients! #community #VHH #savinglives

The Antibody Society

26,242 followers
1mo

In a paper newly published in mAbs, Uppsala University- and Key2Brain AB-affiliated authors presented their latest results using VHH-scFv fusions to penetrate the BBB. From the abstract: We developed and evaluated fusion proteins (FPs) combining VHHs with human IgG Fc domains or single-chain variable fragments (scFvs) of the anti-amyloid-beta (Aβ) antibody 3D6. In vitro assessments showed varying affinities of the FPs for TfR. In vivo evaluations indicated that specific VHH-Fc and VHH-scFv fusions reached significant brain concentrations, emphasizing the importance of optimal TfR binding affinities. The VHH-scFv fusions were further investigated in mouse models with Aβ pathology, showing higher retention compared to wild-type mice without Aβ pathology. Our findings suggest that these novel VHH-based FPs hold potential for therapeutic and diagnostic applications in AD, providing a strategy to overcome BBB limitations and enhance brain targeting of antibody-based treatments. Furthermore, our results suggest that a given bispecific TfR-binding fusion format has a window of “optimal” affinity where parenchymal delivery is adequate, while blood pharmacokinetics aligns with the desired application of the fusion protein. https://lnkd.in/edR2_396

Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood–brain barrier and interacts with amyloid β

tandfonline.com

Like Comment Share
Sauvie Inc.

572 followers
1mo
Report this post
Congratulations Arash Hatefi and team for having another informative article about the Immune Cell Engager published! You are bringing hope to patients!

Arash Hatefi

Professor of Pharmaceutical Sciences
2mo Edited

Colleagues who work with Immune Cell Engagers may find this manuscript interesting! Two findings: 1) Ultra high-affinity Multivalent Immune Cell Engagers can be created by recombinantly fusing VHHs in tandem. 2) Daratumumab-induced NK cell fratricide is due to CD38-CD38 crosslinking and is not related to ADCC via CD16a-CD38 crosslinking.

1 Comment

Like Comment Share
Sauvie Inc. reposted this

The National Institutes of Health

848,911 followers
5mo
Report this post
NIH researchers have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments. The five-drug combination targets multiple molecular pathways that diffuse large B-cell lymphoma (DLBCL) tumors use to survive. https://bit.ly/3RAvj5b #cancer #CancerResearch #CancerTreatment #lymphoma #research #NIH

Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma

nih.gov

3 Comments

Like Comment Share
Sauvie Inc.

572 followers
8mo
Report this post
Sauvie Inc. congratulates Shahryar Khoshtinat Nikkhoi, Arash Hatefi et al for publishing their important work in BMJ evaluating the anticancer activity of the bispecific immune cell engager in NK humanized NOG mice. Very promising to see that the immune cell engager "eliminates cancer metastasis" in this model. https://lnkd.in/d7YSpJnr #immunecellengager #savinglives #innateimmunity #targetedtherapy

Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice

jitc.bmj.com

Like Comment Share
Sauvie Inc.

572 followers
11mo
Report this post
Wishing everyone a warm and joyous Holiday Season. #savinglives #community #holidayseason #thankful
Like Comment Share

Sauvie Inc.

Biotechnology Research

Short Hills, NJ 572 followers

Developing transformational therapies with next generation antibodies.

About us

Products

Single-domain antibody (sdAb)

Locations

Employees at Sauvie Inc.

Scott Oehrlein

Independent Board Director and Biopharma Commercial Consulting

Ken Suh

CEO, Board Director, Investor

Audrey Haukioja

President at Haukioja Consulting Inc

Updates

Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood–brain barrier and interacts with amyloid β

tandfonline.com

Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma

nih.gov

Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice

jitc.bmj.com

Join now to see what you are missing

Similar pages

SAUVIE

Vasomune Therapeutics, Inc.

Double Bond Pharmaceutical International AB

NanoInk Imaging

vivoPharm LLC - A Reaction Biology Company

Robin Hood Ventures

Vivo Bio Tech Ltd.

Artiva Biotherapeutics

Arvinas

CARGO Therapeutics